Identification of a Serum-Induced Transcriptional Signature Associated With Type 1 Diabetes in the BioBreeding Rat

doi:10.2337/db10-0372

Diabetes. 2010 October; 59(10): 2375–2385.

Published online 2010 August 3. doi: 10.2337/db10-0372

PMCID: PMC3279523

Identification of a Serum-Induced Transcriptional Signature Associated With Type 1 Diabetes in the BioBreeding Rat

Mary Kaldunski,¹ Shuang Jia,¹ Rhonda Geoffrey,¹ Joel Basken,¹ Simon Prosser,¹ Sanjay Kansra,¹ John P. Mordes,² Åke Lernmark,³ Xujing Wang,⁴ and Martin J. Hessner¹

¹Max McGee National Research Center for Juvenile Diabetes, Department of Pediatrics at the Medical College of Wisconsin, the Children's Research Institute of Children's Hospital of Wisconsin, and the Human and Molecular Genetics Center, Milwaukee, Wisconsin;

²Division of Endocrinology and Metabolism, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts;

³Robert H. Williams Laboratory, Department of Medicine, University of Washington, Seattle, Washington;

⁴Department of Physics and the Comprehensive Diabetes Center, University of Alabama at Birmingham, Birmingham, Alabama.

Corresponding author: Martin J. Hessner, Email: mhessner/at/mcw.edu.

Received March 17, 2010; Accepted July 12, 2010.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

This article has been cited by other articles in PMC.

Abstract

OBJECTIVE

Inflammatory mediators associated with type 1 diabetes are dilute and difficult to measure in the periphery, necessitating development of more sensitive and informative biomarkers for studying diabetogenic mechanisms, assessing preonset risk, and monitoring therapeutic interventions.

RESEARCH DESIGN AND METHODS

We previously utilized a novel bioassay in which human type 1 diabetes sera were used to induce a disease-specific transcriptional signature in unrelated, healthy peripheral blood mononuclear cells (PBMCs). Here, we apply this strategy to investigate the inflammatory state associated with type 1 diabetes in biobreeding (BB) rats.

RESULTS

Consistent with their common susceptibility, sera of both spontaneously diabetic BB DRlyp/lyp and diabetes inducible BB DR+/+ rats induced transcription of cytokines, immune receptors, and signaling molecules in PBMCs of healthy donor rats compared with control sera. Like the human type 1 diabetes signature, the DRlyp/lyp signature, which is associated with progression to diabetes, was differentiated from that of the DR+/+ by induction of many interleukin (IL)-1–regulated genes. Supplementing cultures with an IL-1 receptor antagonist (IL-1Ra) modulated the DRlyp/lyp signature (P < 10⁻⁶), while administration of IL-1Ra to DRlyp/lyp rats delayed onset (P = 0.007), and sera of treated animals did not induce the characteristic signature. Consistent with the presence of immunoregulatory cells in DR+/+ rats was induction of a signature possessing negative regulators of transcription and inflammation.

CONCLUSIONS

Paralleling our human studies, serum signatures in BB rats reflect processes associated with progression to type 1 diabetes. Furthermore, these studies support the potential utility of this approach to detect changes in the inflammatory state during therapeutic intervention.

Type 1 diabetes is characterized by immune infiltration of the pancreatic islets (insulitis) and destruction of the insulin-producing β-cells. It is modeled by the biobreeding (BB) rat, in which disease is associated with insulitis, hyperglycemia, and exogenous insulin dependency (1,2). Like humans and the nonobese diabetic (NOD) mouse, the major histocompatibility complex (MHC) (insulin-dependent diabetes locus 1 [Iddm1]) contributes the largest genetic risk for type 1 diabetes in BB rats (3,4).

The DRlyp/lyp and DR+/+ congenic BB rat lines differ only by the Iddm2 locus on chromosome 4 (5). Iddm2 has been cloned, and the lymphopenia in DRlyp/lyp rats arises from a mutation in the Gimap5 gene, which encodes a mitochondrial protein necessary for postthymic T-cell survival (6,7). The spontaneously diabetic phenotype, which occurs in 100% of DRlyp/lyp rats during adolescence (65.3 ± 6.3 days), is elicited through deficiency in regulatory T-cells (T_REG cells), as diabetes can be rescued through adoptive transfer of this population (8).

Type 1 diabetes in the nonlymphopenic BB DR+/+ rat, which possesses a wild-type Gimap5, is inducible through depletion of T_REG cells (9,10). Thus, in all BB rats, there is predisposition for type 1 diabetes that is manifest upon loss of immune regulation. This predisposition is absent in Wistar-Furth (WF) rats, which share the RT1^u MHC haplotype, since depletion of T_REG cells does not induce disease. This susceptibility is also absent in Fischer rats, as introgression of RT1^u/u and/or Gimap5^−/− is insufficient for type 1 diabetes development (11).

In addition to T-cell responses, cytokines are important in diabetogenesis (12), as they are associated with β-cell destruction and disease status in both humans and spontaneous rodent models. Previously, we applied a sensitive genomics-based bioassay to investigate the presence of proinflammatory factors in human type 1 diabetes. The approach used sera of patients with recent-onset type 1 diabetes or healthy control subjects to induce transcription in unrelated healthy peripheral blood mononuclear cells (PBMCs) (13). Recent-onset type 1 diabetes sera induced a transcriptional profile that included genes related to innate immunity and genes regulated by interleukin (IL)-1. The signature was distinct from that induced by sera of healthy control subjects or long-standing type 1 diabetic patients, and analysis of a limited number of preonset samples showed that it preceded disease and the development of autoantibodies. Our findings in type 1 diabetes, and those reported for systemic-onset juvenile idiopathic arthritis (14), support that expression signatures induced by serum factors associated with different inflammatory states are disease specific, are reflective of active disease, and are mechanistically informative.

Here, we examine the serum-induced transcriptional signatures of DRlyp/lyp and DR+/+ rats in an attempt to bridge the divide between invasive studies allowed in animal models and the peripheral blood sampling possible in humans. These studies identify an innate immune signature associated with progression to type 1 diabetes in DRlyp/lyp rats that is modulated by the addition of an IL-1 receptor antagonist (IL-1Ra) in vitro and find that administration of IL-1Ra to pre-diabetic animals modulates the inflammatory signature and delays disease onset.

RESEARCH DESIGN AND METHODS

Brown Norway (BN) and BB rats were propagated as described (5,6). Before euthanization, animals were fasted for 16 h, and those possessing blood glucose levels >130 mg/dl were disqualified from studies of pre-diabetes. Rats were anesthetized under isofluorane, and blood was collected by heart puncture. Serum was separated by centrifugation then stored at −80°C until use.

Human recombinant IL-1Ra (hIL-1Ra) (350 μg/kg/day) or vehicle (saline) was delivered to DRlyp/lyp rats by intraperitoneal injection. Dosage was based upon previous hIL-1Ra administration to rodents (15,16). Treatment was initiated by day 30 and continued either through day 40 or through diabetes onset. Diabetes onset was defined as the first of two consecutive blood glucose measurements >250 mg/dl. Survival was analyzed with the Kaplan-Meier method. All procedures were approved by the Medical College of Wisconsin Institutional Animal Care and Use Committee.

PBMC cultures.

Fresh PBMCs of healthy BN rats (~180-day-old males, to avoid variation introduced by estrous or pubertal status) were isolated by density gradient centrifugation. As described (13), transcription was induced by culturing PBMCs for 6 h at 37°C in 5% CO₂ with 20% autologous BN (self-baseline control), allogeneic BN (healthy unrelated control), DRlyp/lyp, or DR+/+ serum. Indicated cultures were supplemented with 1 ng/ml rat IL-1β or 1 μg/ml rat IL-1Ra. RNA was extracted using TRIzol reagent, amplified/labeled using the express kit (Affymetrix, Santa Clara, CA), and hybridized to the Affymetrix Rat Genome 230 2.0 Array. RNA from each culture was independently analyzed. Image data were quantified with Affymetrix Expression Console Software and normalized with Robust Multichip Analysis (www.bioconductor.org/) to determine signal log ratios. ANOVA was conducted and false discovery rates (FDRs) were determined using Partek Genomics Suite version 6.2. To capture the most reliable data, limit the length of gene lists, and facilitate focused pathway analyses, differentially expressed probe sets were defined as those possessing an FDR <10% and |log₂ ratio| >0.5 between the compared groups. Ontological analysis was performed with the Database for Annotation, Visualization, and Integrated Discovery (DAVID) (17). Hierarchical clustering was conducted with Genesis (18). Orthologous rat and human probe sets were mapped using the Affymetrix support document (HG-U133_Plus_2.na29.orthologue.csv.zip). All raw data files have been deposited in The National Center for Biotechnology Information Gene Expression Omnibus (accession no. GSE19537).

Direct detection of inflammatory mediators.

Sera of day 60 BB rats and day 180 BN rats were assayed with the BeadLyte cytokine assay kit (Millipore, Billerica, MA), per the manufacturer's protocol, and a Bio-Plex Luminex 100 XYP instrument. Concentrations were calculated with the Bio-Plex Manager 4.1 software and a five-parameter curve-fitting algorithm applied for standard curve calculations. IL-33 levels in sera and IL-1β/-α levels in conditioned culture medium were measured with Quantikine enzyme-linked immunosorbent assays (ELISAs) (R&D Systems, Minneapolis, MN), and gram-negative bacterial endotoxins (lipopolysaccarides [LPS]) were measured by the Limulus amoebocyte lysate assay (Associates of Cape Cod, Falmouth, MA).

Western blot analysis for anti–hIL-1Ra antibodies.

hIL-1Ra (17 kDa) was electrophoresed through polyacrylamide gels (10–20% Tris-HCl) and transferred to polyvinylidene difluoride membranes. Membranes were blocked for 1 h with 5% BSA and 0.1% Tween-20 at room temperature then probed with a 1:2,000 dilution of sera from hIL-1Ra or saline-treated DRlyp/lyp rats overnight at 4^ο C. Blots were washed three times with 1 × TBS with 0.1% Tween 20 then incubated with a 1:2,000 dilution of anti-rat IgG, horseradish peroxidase–linked antibody in blocking solution for 1 h at room temperature. After three washes, the Enhanced Chemiluminescence (ECL) Plus System (Amersham, Piscataway, NJ) was used for visualization.

RESULTS

Induction of transcriptional signatures.

To determine whether inflammatory mediators related to diabetogenesis could be detected through their ability to induce transcription, PBMCs of healthy, day 180 BN rats were cultured with day 60 DRlyp/lyp (representing the period immediately before onset), day 60 DR+/+, allogeneic BN, or autologous BN serum. To ensure induced transcription was not related to elevated blood glucose levels, only sera of normoglycemic, preonset rats were used. In preliminary studies, we observed that day 60 DRlyp/lyp serum, like human recent-onset sera, induced many genes regulated by IL-1. Therefore, PBMCs were also cultured with day 60 DRlyp/lyp serum supplemented with IL-1Ra as well as autologous BN serum supplemented with IL-1β, to respectively block or induce IL-1–mediated gene expression. Culture of BN PBMCs with DRlyp/lyp or DR+/+ sera regulated, within the threshold values, 1,979 and 2,904 probe sets, respectively, relative to culture with allogeneic BN sera.

Analysis of genes commonly regulated by day 60 DR+/+ and DRlyp/lyp sera.

As reflected in the Venn diagram illustrated in Fig. 1A, culture of BN PBMCs with either DRlyp/lyp or DR+/+ sera regulated a total of 3,971 probe sets (supplement A Fig. 1A, available at http://diabetes.diabetesjournals.org/cgi/content/full/db10-0372/DC1). Consistent with type 1 diabetes susceptibility in both strains, the signatures share a significantly nonrandom (P < 10⁻⁶, χ² test), commonly regulated intersection of 912 probe sets that represents 46.1 and 31.4% of the probe sets induced by either DRlyp/lyp or DR+/+ serum, respectively. Hierarchical clustering (Fig. 1B) shows the relatedness of the five experimental conditions for this subset. These 912 shared probe sets were annotated with DAVID, which identified significantly regulated gene ontology biological processes related to immunological activation, antigen presentation, and intracellular signaling, in particular through the nuclear factor (NF) κB pathway (Table 1 and supplement B).

FIG. 1.

Analysis of genes commonly regulated by day 60 DR+/+ and DRlyp/lyp sera relative to allogeneic BN sera. PBMCs of four BN rats each were cultured under six different conditions: 1) autologous serum (n = 4 cultures), 2) autologous serum spiked with IL-1β (more ...)

TABLE 1

Significantly regulated gene ontology biological processes

NFκB is a transcriptional regulator of innate and adaptive immunity (19) that is activated through events such as binding of IL-1 to IL-1R1 or LPS to toll-like receptor (TLR) 4. These events converge at a set of I-κB kinases that phosphorylate the inhibitory I-κB proteins (NFKBIA and NFKBIB) leading to their degradation, allowing release and nuclear translocation of cytoplasmic NFκB, where it facilitates target gene transcription. Both DRlyp/lyp and DR+/+ sera induced Nfkb2, which encodes the p100 precursor that is cleaved to produce the NFκB p52 protein; the receptor-interacting serine-threonine kinase 2 (Ripk2), a potent activator of NFκB; as well as tumor necrosis factor (TNF) receptor superfamily member 25 (Tnfrsf25), which stimulates NFκB activity (20). Sera of either BB rat induced transcription of genes related to intracellular signaling, including signal transducer and activator of transcription 2 (Stat2) and mitogen-activated protein kinase activated protein kinase 5 (Mapkapk5), which is activated by MAPKs in response to exposure to proinflammatory cytokines. DRlyp/lyp and DR+/+ sera also induced transcription of genes encoding chemokines (Ccl2, Cxcl16) and receptors including Tlr4, Tlr7, Ccr1, and Cd14, which are important in TLR4 signaling. Other genes related to immune function included IL-1R–associated kinase 3 (Irak3) and intercellular adhesion molecule 1 (Icam1). Both DRlyp/lyp and DR+/+ sera induced the transcription factor Kruppel-like factor 2 (Klf2), an inflammatory inhibitor that functions through the binding of coactivators necessary for optimal NFκB activity (21), and B-cell CLL/lymphoma three (BclIII), an IL-10–inducible gene that impairs binding of NFκB complexes to DNA (19,22). Importantly, all 912 probe sets of the intersection exhibited directionally concordant inductions by either DRlyp/lyp or DR+/+ sera relative to allogeneic BN sera. Furthermore, when directly comparing expression levels between the DRlyp/lyp and DR+/+, only two probes sets (2 of 912, 0.2%) were differentially expressed (Klf4 and Map4k2, supplement A). Overall, analysis of the intersection revealed that culturing BN PBMCs with either DR+/+ or DRlyp/lyp sera, compared with allogeneic BN sera, induced transcription consistent with immunological activation (Fig. 1C).

Independent analysis of genes regulated by DRlyp/lyp and DR+/+ sera.

To reveal processes associated with progression to type 1 diabetes, the DRlyp/lyp and DR+/+ serum signatures were independently analyzed. The mean expression from each of the five experimental conditions was subjected to hierarchical clustering using the 1,979 or 2,904 probe sets respectively regulated by DRlyp/lyp sera or DR+/+ sera relative to the BN allogeneic induction (Figs. 2A and C). Ontological analysis of the DRlyp/lyp signature identified biological processes related to proinflammatory processes possessing higher numbers of associated genes with greater significance compared with the analyses of the DRlyp/lyp:DR+/+ intersection or the DR+/+ signature (Table 1 and supplement B). Specifically, DRlyp/lyp sera regulated biological processes related to antigen presentation, inflammation, and leukocyte migration. Annotated genes related to these functions included induction of Il1b, Tlr2, Il18, Icam2, proteasome subunit β type 1, (Psmb1), Stat1, and numerous MHC class II genes. Among the 1,979 probe sets regulated by DRlyp/lyp sera were central components of the NFκB cascade, including Nfkbia and Nfkbib, as well as positive regulators of NFκB activity, including casein kinase 2 β subunit (Csnk2b), a potent NFκB activator that directly phosphorylates NFKBIA (23), baculoviral IAP repeat-containing 2 (Birc2) (20), and Cd40 (Fig. 3A and supplement A).

FIG. 2.

Independent analysis of genes regulated by DRlyp/lyp and DR+/+ sera. In all cases, replicates were averaged and the relatedness of the five conditions was analyzed by hierarchical clustering. A: Illustrates all probe sets regulated between the DRlyp/lyp (more ...)

FIG. 3.

Well-annotated regulated probe sets were uniquely identified in the DRlyp/lyp vs. BN allogeneic induction (A) or the DR+/+ vs. BN allogeneic induction (B). *Orthologues regulated by human type 1 diabetes sera (13). The scale represents the fold of change (more ...)

When examining the 1,067 probe sets uniquely regulated by DRlyp/lyp sera (i.e., those excluding the intersection) (Fig. 2B), a role for IL-1 in induction of the signature became evident, as blocking IL-1R1 by adding IL-1Ra to cultures modulated the signature, yielding one more similar to that induced by DR+/+ sera. Specifically, after adding IL-1Ra to the culture, expression of 83.3% (889 of 1,067) of the DRlyp/lyp-specific probe sets no longer met the threshold values (P < 10⁻⁶, χ² test). Among 912 genes of the intersection, only 40% (374) were influenced by the addition of IL-1Ra (P < 10⁻⁶, χ² test). When examining 1,992 probe sets uniquely regulated by DR+/+ sera (Fig. 2D), addition of IL-1Ra to the DRlyp/lyp culture resulted in induction of a signature more similar to that of the DR+/+ culture in terms of fold of change. However, the overall expression levels were less influenced, in that among 1,992 genes regulated in the DR+/+ culture, only 26.2% (521 of 1,992) of the probe sets in the DRlyp/lyp + IL-1Ra culture were regulated to meet the threshold values. These statistical findings are reflected in Figs. 2B and D and show gene expression arising through IL-1R1 signaling accounts for a large part of the difference between the DRlyp/lyp and DR+/+ signatures. Furthermore, addition of IL-1Ra to DRlyp/lyp cultures reduced gene expression annotated as proinflammatory (Fig. 2B) and enhanced gene expression annotated as being regulatory (Fig. 2D). Addition of IL-1β to PBMCs cultured with autologous BN sera induced a modest signature, more similar to that induced by that of BB rat sera than cultures possessing BN allogeneic sera (Fig. 2), regulating 209 of 3,971 probe sets regulated by DR+/+ or DRlyp/lyp serum relative to BN allogeneic serum.

Overall, the ontological analysis of 2,904 probe sets regulated by DR+/+ sera revealed the greatest number of highly significant biological processes, and these annotations were primarily related to regulation of gene expression (Table 1 and supplement B). Numerous genes related to negative regulation of inflammation and NFκB signaling were regulated by DR+/+ sera, including Nfkbie, an inhibitor of NFκB (24); the transcriptional repressors zinc finger E-box binding homeobox 1 (Zeb1); zinc finger and BTB domain containing 7a (Zbtb7a); interferon regulatory factor 2 (Irf2); ETS domain-containing protein Elk-3; the inhibitor of activated STAT 2 (Pias2); suppressor of cytokine signaling-5 (Socs5); the cell cycle inhibitor; myeloid/lymphoid or mixed-lineage leukemia 5 (Mll5); and others (Fig. 3B).

While the sera of either BB substrain induced gene expression consistent with immune activation, DRlyp/lyp sera induced an inflammatory signature consistent with the presence of IL-1, whereas that of the DR+/+ sera can be characterized as largely immunoregulatory. Among the genes regulated by DRlyp/lyp and DR+/+ sera were 87 orthologues previously identified among 587 genes regulated by human type 1 diabetes sera (Figs. 1 and and33 and supplement A) (13).

Direct detection of inflammatory mediators.

In an effort to account for the induced signatures, cytokine levels were measured by ELISA in the DRlyp/lyp, DR+/+, and BN sera used in the expression studies (Table 2). Measurable differences in IL-1α or IL-1β levels between DRlyp/lyp, DR+/+, or BN rat sera were not detected, raising the question whether the induced transcription measured after 6 h of culture was a primary effect of IL-1 on the PBMCs or a secondary effect of IL-1 produced by the PBMCs in response to other dilute mediators in DRlyp/lyp sera. Conditioned medium of cultures supplemented with the various sera were assayed for IL-1α and IL-1β at 0, 1, 3, 6, 12, and 24 h. While IL-1α was not detected at all, significant detectable levels of IL-1β were measured in only DRlyp/lyp cultures at 24 h but not at or prior to 6 h (Table 3). This supports the hypothesis that the 6 h transcriptional response is primary and is due in part to IL-1 itself, as lower IL-1β protein was not significantly detected in the DR+/+ and DRlyp/lyp + IL-1Ra cultures. This parallels the significant detection of Il1b transcript only in cultures supplemented with DRlyp/lyp sera. Significant differences in serum IL-10 were not observed; however, consistent with the transcriptional signatures, levels in DR+/+ and DRlyp/lyp serum were greater than that measured in the BN rat. IL-13 was the only significantly upregulated cytokine detected in serum of the day 60 DRlyp/lyp rat.

TABLE 2

Cytokine/chemokine levels in DRlyp/lyp, DR+/+, and BN rats

TABLE 3

IL-1β levels in conditioned medium after PBMC culture with DRlyp/lyp, DR+/+, and BN sera

Recent studies have identified increased levels of LPS in human type 1 diabetic patients (25). Given that TLR4 and IL-1R1 signaling both are mediated through the adaptor protein MyD88 to activate NFκB, we investigated LPS serum levels. On average, significantly higher LPS levels were detected in the DRlyp/lyp and DR+/+ rat serum compared with that of BN rats (Table 2), consistent with the significant induction of Il1b transcript in cultures possessing with DRlyp/lyp sera even when supplemented with IL-1Ra (supplement A).

Delay of BB rat type 1 diabetes through IL-1R blockade.

Given the parallels between the signatures induced by human type 1 diabetes and DRlyp/lyp sera, in terms of overrepresentation of transcripts regulated by IL-1 and modulation of the DRlyp/lyp signature upon addition of IL-1Ra to cultures, we tested the effectiveness of IL-1Ra in delaying type 1 diabetes onset in BB rats. The treatment of BB rats with rat IL-1Ra is cost prohibitive, while hIL-1Ra shares >70% amino acid homology with rat IL-1Ra and is bioactive in rat (15,26). Thus, we reasoned that if IL-1–mediated inflammation was relevant to diabetogenesis in DRlyp/lyp rats, treatment with hIL-1Ra should delay onset for approximately the amount of time required to mount a robust antibody response (~10–14 days). Treatment was initiated by day 30 and continued through type 1 diabetes onset. Treated rats survived 71 ± 11 days, whereas controls survived 61 ± 6 days (P = 0.007) (Fig. 4A). Significant differences in weight or growth rate were not observed between treated and control rats (P > 0.05). As expected, the animals possessed antibody titer to hIL-1Ra (Fig. 4B).

FIG. 4.

Treatment of DRlyp/lyp rats with hIL-1Ra. A: Longitudinal monitoring of DRlyp/lyp rats treated with 350 μg/kg/day human recombinant IL-1Ra (n = 16, dashed line) or saline (n = 23, solid line). Agents were delivered intraperitoneally in saline. (more ...)

Use of transcriptional signature to monitor effect of IL-1R blockade.

To determine whether hIL-1Ra treatment of DRlyp/lyp rats would result in modulation of the serum signature, additional rats were treated with hIL-1Ra or saline for 10 days, beginning at day 30. Serum was collected at day 40 and assayed to determine 1) whether an inflammatory signature was present at this time prior to insulitis (27), 2) whether day 40 and day 60 signatures were similar, and 3) whether a day 40 signature was modulated in hIL-1Ra–treated rats. Furthermore, after only 10 days of treatment, the effect of hIL-1Ra treatment would be less likely masked by the high concentrations of neutralizing antibodies observed at onset (Fig. 4B, lower panels).

Regulated probe sets between cultures possessing serum of saline- or hIL-1Ra–treated DRlyp/lyp rats compared with allogeneic BN serum were identified and subjected to hierarchical clustering (Fig. 4C and D). In the PBS-treated DRlyp/lyp versus BN allogeneic comparison, 1,526 probe sets met these criteria, and among these, a significant percentage (638 of 1,526, 41.8%; P < 10⁻⁶ χ² test) were also regulated by day 60 DRlyp/lyp sera. Ontological analysis again identified biological processes related to antigen presentation, inflammation, leukocyte migration, and activation of the NFκB cascade (Table 1 and supplement 2). Selected genes related to these pathways are shown (Fig. 4E, supplement A). Compared with BN sera, sera of day 40 DRlyp/lyp rats treated with hIL-1Ra regulated only five probe sets. The two probe sets of the intersection exhibited directionally concordant inductions by either saline-treated DRlyp/lyp or IL-1Ra–treated DRlyp/lyp sera relative to allogeneic BN sera. As reflected by the fold changes illustrated in Fig. 4D, treatment reduced induction of the proinflammatory signature observed in PBS-treated rats. Overall, these results show that like human type 1 diabetes (13), a serum-induced signature with identity to that observed at onset is detected prior to onset in the DRlyp/lyp rat. Moreover, this signature is modulated by treating rats with hIL-1Ra, suggesting that this approach may prove useful in monitoring the effect of therapeutic interventions in human type 1 diabetes.

DISCUSSION

Previously, we defined a transcriptional signature induced by sera of human type 1 diabetic patients (13). Here, parallel studies were conducted that defined unique signatures for diabetes-inducible DR+/+ and spontaneously diabetic DRlyp/lyp rats. Like human type 1 diabetes, the signature associated with disease progression in DRlyp/lyp rats includes many genes regulated by IL-1 and differential regulation of NFκB signaling is a key feature distinguishing the signatures induced by sera of the DRlyp/lyp and DR+/+ substrains.

Identity is observed between signatures induced by day 60 serum of DRlyp/lyp and DR+/+ rats, in particular the 912 probe sets of the DRlyp/lyp:DR+/+ intersection. Identity is also evident in 1,992 probe sets regulated to threshold levels by DR+/+ serum. These probe sets, annotated as immunoregulatory, are regulated by DRlyp/lyp serum to a lesser degree that does not meet threshold values. This suggests the presence of endogenous, albeit insufficient, immunoregulatory activity in DRlyp/lyp rats and may explain why relatively few (10⁶) adoptively transferred DR+/+ T_REG cells prevent type 1 diabetes in DRlyp/lyp rats (8). Conversely, from the perspective of the probe sets regulated by DRlyp/lyp sera, the DRlyp/lyp and DR+/+ signatures are distinct, with the DRlyp/lyp signature possessing an IL-1–driven component that is downregulated by adding IL-1Ra to the culture.

Among human type 1 diabetic patients, a significant percentage will develop autoimmune thyroid disease (28). Likewise, lymphopenic BB rats develop autoimmune thyroiditis. Since the method measures the sum of the inflammatory factors present in serum, we cannot exclude that thyroid autoimmunity has not contributed to the signature defined for DRlyp/lyp rats. In terms of other models, we have examined serum signatures associated with type 1 diabetes in LEW.1WR1 rats (29) and find the inflammatory states distinct but sharing partial identity (supplement C) (30).

Despite the challenges of directly measuring peripheral cytokine levels in human type 1 diabetes, studies have established that a complex cytokine milieu exists. This includes elevated IL-1 family members in patient cohorts before and after disease onset (31 –35). Here, ELISA analysis was unable to detect differences in IL-1β/-α levels between DRlyp/lyp, DR+/+ or BN rat sera. This may be related to assay sensitivity, the limited number of rats analyzed, or presence of soluble IL-1 receptors, which impairs detection of free bioactive IL-1 and highlights the need for new, more sensitive biomarkers. Given that the amount of IL-1β (1 ng/ml) spiked into the autologous BN cultures exceeded the sensitivity of the multiplex cytokine analysis for IL-1α (>27 pg/ml) and IL-1β (>27 pg/ml), the signatures induced by DRlyp/lyp and DR+/+ sera (in particular genes of the intersection) are not likely an effect of IL-1 concentrations exclusively but involve the contribution of other inflammatory mediators. Binding of IL-1 and LPS to their respective receptors initiate transcriptional programs similar to those observed. We found LPS levels in BB rats nearly twice that of BN rats, consistent with reported intestinal hyperpermeability in BB rats (36), which may lead to the translocation of bacteria and/or endotoxin and a heightened systemic inflammatory state. IL-13 was elevated in DRlyp/lyp compared with DR+/+ and BN serum. This is consistent with elevated IgE levels and eosinophilia prior to onset in DRlyp/lyp rats (37), as IL-13 induces immunoglobulin isotype switching to IgE in B-cells and regulates eosinophilic inflammation.

In vitro, human and rodent pancreatic β-cells are highly susceptible to the actions of IL-1 (38), and IL-1Ra can protect β-cells from the downstream consequences of IL-1 exposure (39). While IL-1 transcript and protein are detected within immune infiltrated pancreatic islets of BB rats and NOD mice (40 –42), in vivo modulation of either ligand or receptor in these models has yielded mixed results. Administration of high doses of IL-1 to diabetes-prone BB rats induced higher blood glucose concentrations before and at type 1 diabetes onset and accelerated onset (43). In contrast, administration of IL-1 to the NOD mouse delayed onset and reduced incidence (44,45). IL-1R deficiency in the NOD mouse slowed progression to type 1 diabetes but did not prevent it (46), and treatment of NOD mice with IL-1Ra inhibited recurrence of type 1 diabetes after islet transplantation (47). IL-1 has been shown to exacerbate autoimmunity by promoting expansion of effector T-cells and attenuating T_REG cell function (48), raising the possibility of IL-1–mediated impaired regulatory function of T_REG cells in DRlyp/lyp relative to DR+/+ rats. Treatment of DRlyp/lyp rats with hIL-1Ra delayed onset for the time required to mount a neutralizing humoral immune response. These results are consistent with a previous study in which hIL-1Ra delayed BB rat type 1 diabetes onset but did not affect growth or modify lymphocyte counts (16). As reported here, anti–hIL-1Ra antibodies developed, to which short-term protection (2–3 weeks) was attributed. Importantly, with delayed onset we observe modulation of the serum-induced transcriptional profile in hIL-1Ra–treated rats.

These findings support that this bioassay may not only have utility as an early mechanistically informative inflammatory biomarker of type 1 diabetes but may prove useful in monitoring changes in inflammatory state during therapeutic interventions, including those targeting IL-1 (49).

Supplementary Material

Online Appendix

Click here to view.

ACKNOWLEDGMENTS

This work was supported by National Institute of Allergy and Infectious Diseases (NIAID) Grants R01AI078713 (to M.J.H.) and P01AI42380 (to Å.L.); National Institute of Diabetes and Digestive and Kidney Diseases Grant R01DK080100 (to X.W.); Juvenile Diabetes Research Foundation International Grant 1-2008-1026 (to M.J.H); Advancing a Healthier Wisconsin Initiative Grant 5520065 (to M.J.H.); and The Children's Hospital of Wisconsin Foundation.

No potential conflicts of interest relevant to this article were reported.

M.K., R.G., J.B., S.P., and S.K. conducted all laboratory studies. S.J. and X.W. conducted all bioinformatic and statistical analyses. Comparative studies of serum signatures between BB and LEW.1WR1 rats were done in collaboration with J.P.M. M.K., S.P., S.K., X.W., and Å.L. reviewed/edited the manuscript. M.J.H designed/directed the study and wrote/reviewed/edited the manuscript.

The authors are grateful to Sanja Glisic, PhD, and Parthav Jailwala, MS, at The Medical College of Wisconsin for their critical review of this manuscript. We thank Shouguo Gao, PhD, at the University of Alabama at Birmingham for helpful discussions on statistical issues. Multiplex cytokine assays were conducted at the Baylor Institute for Immunology Research NIAID Cooperative Centers Luminex Core Facility under the direction of John Connolly, PhD.

Footnotes

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

REFERENCES

1. Crisa L, Mordes JP, Rossini AA. Autoimmune diabetes mellitus in the BB rat. Diabetes Metab Rev 1992;8:4–37. [PubMed]

2. Scott J. The spontaneously diabetic BB rat: sites of the defects leading to autoimmunity and diabetes mellitus: a review. Curr Top Microbiol Immunol 1990;156:1–14. [PubMed]

3. Colle E, Ono SJ, Fuks A, Guttmann RD, Seemayer TA. Association of susceptibility to spontaneous diabetes in rat with genes of major histocompatibility complex. Diabetes 1988;37:1438–1443. [PubMed]

4. Awata T, Guberski DL, Like AA. Genetics of the BB rat: association of autoimmune disorders (diabetes, insulitis, and thyroiditis) with lymphopenia and major histocompatibility complex class II. Endocrinology 1995;136:5731–5735. [PubMed]

5. Bieg S, Koike G, Jiang J, Klaff L, Pettersson A, MacMurray AJ, Jacob HJ, Lander ES, Lernmark A. Genetic isolation of iddm 1 on chromosome 4 in the biobreeding (BB) rat. Mamm Genome 1998;9:324–326. [PubMed]

6. MacMurray AJ, Moralejo DH, Kwitek AE, Rutledge EA, Van Yserloo B, Gohlke P, Speros SJ, Snyder B, Schaefer J, Bieg S, Jiang J, Ettinger RA, Fuller J, Daniels TL, Pettersson A, Orlebeke K, Birren B, Jacob HJ, Lander ES, Lernmark A. Lymphopenia in the BB rat model of type 1 diabetes is due to a mutation in a novel immune-associated nucleotide (Ian)-related gene. Genome Res 2002;12:1029–1039. [PubMed]

7. Daheron L, Zenz T, Siracusa LD, Brenner C, Calabretta B. Molecular cloning of Ian4: a BCR/ABL-induced gene that encodes an outer membrane mitochondrial protein with GTP-binding activity. Nucleic Acid Res 2001;29:1308–1316. [PMC free article] [PubMed]

8. Poussier P, Ning T, Murphy T, Dabrowski D, Ramanathan S. Impaired post-thymic development of regulatory CD4+25+ T cells contributes to diabetes pathogenesis in BB rats. J Immunol 2005;174:4081–4089. [PubMed]

9. Martin AM, Maxson MN, Leif J, Mordes JP, Greiner DL, Blankenhorn EP. Diabetes-prone and diabetes-resistant BB rats share a common major diabetes susceptibility locus, iddm4: additional evidence for a “universal autoimmunity locus” on rat chromosome 4. Diabetes 1999;48:2138–2144. [PubMed]

10. Zipris D, Hillebrands JL, Welsh RM, Rozing J, Xie JX, Mordes JP, Greiner DL, Rossini AA. Infections that induce autoimmune diabetes in BBDR rats modulate CD4+CD25+ T cell populations. J Immunol 2003;170:3592–3602. [PubMed]

11. Hornum L, Lundsgaard D, Markholst H. An F344 rat congenic for BB/DP rat-derived diabetes susceptibility loci Iddm1 and Iddm2. Mamm Genome 2001;12:867–868. [PubMed]

12. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001;358:221–229. [PubMed]

13. Wang X, Jia S, Geoffrey R, Alemzadeh R, Ghosh S, Hessner MJ. Identification of a molecular signature in human type 1 diabetes mellitus using serum and functional genomics. J Immunol 2008;180:1929–1937. [PubMed]

14. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005;201:1479–1486. [PMC free article] [PubMed]

15. Badovinac V, Mostarica-Stojkovic M, Dinarello CA, Stosic-Grujicic S. Interleukin-1 receptor antagonist suppresses experimental autoimmune encephalomyelitis (EAE) in rats by influencing the activation and proliferation of encephalitogenic cells. J Neuroimmunol 1998;85:87–95. [PubMed]

16. Dayer-Metroz M-D, Duhamel D, Rufer N, Izui S, Carmichaels D, Wollheim CB, Thompson RC, Dayer J-M. IL-1 receptor antagonist delays spontaneous autoimmune diabetes in BB rats (Abstract). European J Clin Invest 1992;22:A285.

17. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44–57. [PubMed]

18. Sturn A, Quackenbush J, Trajanoski Z. Genesis: cluster analysis of microarray data. Bioinformatics 2002;18:207–208. [PubMed]

19. Ghosh S, Hayden MS. New regulators of NF-kappaB in inflammation. Nat Rev Immunol 2008;8:837–848. [PubMed]

20. Halsey TA, Yang L, Walker JR, Hogenesch JB, Thomas RS. A functional map of NFkappaB signaling identifies novel modulators and multiple system controls. Genome Biol 2007;8:R104. [PMC free article] [PubMed]

21. Das H, Kumar A, Lin Z, Patino WD, Hwang PM, Feinberg MW, Majumder PK, Jain MK. Kruppel-like factor 2 (KLF2) regulates proinflammatory activation of monocytes. Proc Natl Acad Sci U S A 2006;103:6653–6658. [PubMed]

22. Kuwata H, Watanabe Y, Miyoshi H, Yamamoto M, Kaisho T, Takeda K, Akira S. IL-10-inducible Bcl-3 negatively regulates LPS-induced TNF-alpha production in macrophages. Blood 2003;102:4123–4129. [PubMed]

23. McElhinny JA, Trushin SA, Bren GD, Chester N, Paya CV. Casein kinase II phosphorylates I kappa B alpha at S-283, S-289, S-293, and T-291 and is required for its degradation. Mol Cell Biol 1996;16:899–906. [PMC free article] [PubMed]

24. Whiteside ST, Epinat JC, Rice NR, Israel A. I kappa B epsilon, a novel member of the I kappa B family, controls RelA and cRel NF-kappa B activity. Embo J 1997;16:1413–1426. [PubMed]

25. Devaraj S, Dasu MR, Park SH, Jialal I. Increased levels of ligands of toll-like receptors 2 and 4 in type 1 diabetes. Diabetologia 2009;52:1665–1668. [PMC free article] [PubMed]

26. Roderfeld M, Geier A, Dietrich CG, Siewert E, Jansen B, Gartung C, Roeb E. Cytokine blockade inhibits hepatic tissue inhibitor of metalloproteinase-1 expression and up-regulates matrix metalloproteinase-9 in toxic liver injury. Liver Int 2006;26:579–586. [PubMed]

27. Hessner MJ, Wang X, Meyer L, Geoffrey R, Jia S, Fuller J, Lernmark A, Ghosh S. Involvement of eotaxin, eosinophils, and pancreatic predisposition in development of type 1 diabetes mellitus in the BioBreeding rat. J Immunol 2004;173:6993–7002. [PubMed]

28. Van den Driessche A, Eenkhoorn V, Van Gaal L, De Block C. Type 1 diabetes and autoimmune polyglandular syndrome: a clinical review. Neth J Med 2009;67:376–387. [PubMed]

29. Mordes JP, Guberski DL, Leif JH, Woda BA, Flanagan JF, Greiner DL, Kislauskis EH, Tirabassi RS. LEW. 1WR1 rats develop autoimmune diabetes spontaneously and in response to environmental perturbation. Diabetes 2005;54:2727–2733. [PMC free article] [PubMed]

30. Hessner MJ, Blankenhorn EP, Mordes JP. What makes type 1 diabetes (T1D) mainly a disorder of the young? Abstract presented at the 10th International Congress of the Immunology of Diabetes Society (IDS10), Malmo, Sweden, 17–20 May 2009.

31. Luger A, Schernthaner G, Urbanski A, Luger TA. Cytokine production in patients with newly diagnosed insulin-dependent (type I) diabetes mellitus. Eur J Clin Invest 1988;18:233–236. [PubMed]

32. Perez F, Oyarzun A, Carrasco E, Angel B, Albala C, Santos JL. Plasma levels of interleukin-1beta, interleukin-2 and interleukin-4 in recently diagnosed type 1 diabetic children and their association with beta-pancreatic autoantibodies. Rev Med Chil 2004;132:413–420 [in Spanish] [PubMed]

33. Hussain MJ, Peakman M, Gallati H, Lo SS, Hawa M, Viberti GC, Watkins PJ, Leslie RD, Vergani D. Elevated serum levels of macrophage-derived cytokines precede and accompany the onset of IDDM. Diabetologia 1996;39:60–69. [PubMed]

34. Dogan Y, Akarsu S, Ustundag B, Yilmaz E, Gurgoze MK. Serum IL-1beta, IL-2, and IL-6 in insulin-dependent diabetic children. Mediators Inflamm 2006;2006:59206. [PMC free article] [PubMed]

35. Netea MG, Hancu N, Blok WL, Grigorescu-Sido P, Popa L, Popa V, van der Meer JW. Interleukin 1 beta, tumour necrosis factor-alpha and interleukin 1 receptor antagonist in newly diagnosed insulin-dependent diabetes mellitus: comparison to long-standing diabetes and healthy individuals. Cytokine 1997;9:284–287. [PubMed]

36. Vaarala O, Atkinson MA, Neu J. The “perfect storm” for type 1 diabetes: the complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. Diabetes 2008;57:2555–2562. [PMC free article] [PubMed]

37. Geoffrey R, Jia S, Kwitek AE, Woodliff J, Ghosh S, Lernmark A, Wang X, Hessner MJ. Evidence of a functional role for mast cells in the development of type 1 diabetes mellitus in the BioBreeding rat. J Immunol 2006;177:7275–7286. [PubMed]

38. Corbett JA, Sweetland MA, Wang JL, Lancaster JR, Jr, McDaniel ML. Nitric oxide mediates cytokine-induced inhibition of insulin secretion by human islets of Langerhans. Proc Natl Acad Sci U S A 1993;90:1731–1735. [PubMed]

39. Giannoukakis N, Rudert WA, Ghivizzani SC, Gambotto A, Ricordi C, Trucco M, Robbins PD. Adenoviral gene transfer of the interleukin-1 receptor antagonist protein to human islets prevents IL-1β–induced β-cell impairment and activation of islet cell apoptosis in vitro. Diabetes 1999;48:1730–1736. [PubMed]

40. Mandrup-Poulsen T. The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia 1996;39:1005–1029. [PubMed]

41. Jiang Z, Woda BA. Cytokine gene expression in the islets of the diabetic Biobreeding/Worcester rat. J Immunol 1991;146:2990–2994. [PubMed]

42. Zunino SJ, Jiang N, Sambrook JF, Gething MJH. Interleukin 1 alpha expression in islets of NOD mice. FASEB J 1992;6:A1780.

43. Reimers JI, Morch L, Markholst H, Wogensen LD, Andersen HU, Mandrup-Poulsen T, Nerup J. Interleukin-1 beta (IL-1) does not reduce the diabetes incidence in diabetes-prone BB rats. Autoimmunity 1994;17:105–118. [PubMed]

44. Satoh J, Seino H, Abo T, Tanaka S, Shintani S, Ohta S, Tamura K, Sawai T, Nobunaga T, Oteki T, et al. Recombinant human tumor necrosis factor alpha suppresses autoimmune diabetes in nonobese diabetic mice. J Clin Invest 1989;84:1345–1348. [PMC free article] [PubMed]

45. Jacob CO, Aiso S, Michie SA, McDevitt HO, Acha-Orbea H. Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): similarities between TNF-alpha and interleukin 1. Proc Natl Acad Sci U S A 1990;87:968–972. [PubMed]

46. Thomas HE, Irawaty W, Darwiche R, Brodnicki TC, Santamaria P, Allison J, Kay TW. IL-1 receptor deficiency slows progression to diabetes in the NOD mouse. Diabetes 2004;53:113–121. [PubMed]

47. Sandberg JO, Eizirik DL, Sandler S. IL-1 receptor antagonist inhibits recurrence of disease after syngeneic pancreatic islet transplantation to spontaneously diabetic non-obese diabetic (NOD) mice. Clin Exp Immunol 1997;108:314–317. [PubMed]

48. O'Sullivan BJ, Thomas HE, Pai S, Santamaria P, Iwakura Y, Steptoe RJ, Kay TW, Thomas R. IL-1 beta breaks tolerance through expansion of CD25+ effector T cells. J Immunol 2006;176:7278–7287. [PubMed]

49. Pickersgill LM, Mandrup-Poulsen TR. The anti-interleukin-1 in type 1 diabetes action trial–background and rationale. Diabetes Metab Res Rev 2009;25:321–324. [PubMed]

Articles from Diabetes are provided here courtesy of
American Diabetes Association